King Pharmaceuticals KG Investments, Gross Unrealized Gain (Loss), Net of Deferred Income Tax Expense
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept kg:InvestmentsGrossUnrealizedGainLossNetOfDeferredIncomeTaxExpense.
The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about King Pharmaceuticals's investments, gross unrealized gain (loss), net of deferred income tax expense.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is King Pharmaceuticals's investments, gross unrealized gain (loss), net of deferred income tax expense?
- King Pharmaceuticals (KG) reported investments, gross unrealized gain (loss), net of deferred income tax expense of $59K in Q1 2026.